Riskpilot← Back to searchSign inGet full accessCytoki Pharma ApS
APSIn liquidationCVR 40594132Vandtårnsvej 77Research and experimental development on natural sciences and engineering · NACE 7210Est. 20193 employees
Revenue 2025
DKK -42,2M
+8% vs 2024
EBITDA margin
117.2%
-7% vs 2024
Equity ratio
75.0%
Financial strength
Net profit 2025
DKK -43,8M
-12% vs 2024
| Revenue | DKK -42,2M | +8% |
| EBITDA | DKK -49,5M | -7% |
| Net profit | DKK -43,8M | -12% |
| Total assets | DKK 18M | -71% |
| Equity | DKK 13,5M | -76% |
| Employees | 3 | — |
Legal name
Cytoki Pharma ApS
CVR number
40594132
Legal form
Anpartsselskab
NACE code
7210 · Research and experimental development on natural sciences and engineering
Founded
12. juni 2019
Share capital
DKK 357.289
Employees
3 (FTE)
VAT registered
Yes
Audit selected
Yes
Last report
2025-12-31
Financial year
January – December
Signatory rights
Virksomheden tegnes af en likvidator
Company purpose
Selskabets formål er forskning, udvikling, fremstilling og kommercialisering af proteinbaserede lægemidler og hermed efter bestyrelsens skøn stående relateret virksomhed.
Address
Vandtårnsvej 77
Email
rj@cytokipharma.com
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|
| Revenue | -2.124 | -6.040 | -31.975 | -98.764 | -61.548 | -39.133 | -42.199 |
| Staff expenses | -734 | -1.448 | -4.987 | -8.079 | -8.546 | -7.178 | -7.262 |
| EBITDA | -2.858 | -7.488 | -36.962 | -106.843 | -70.094 | -46.310 | -49.461 |
| Depreciation & amort. | -0 | -0 | -0 | -0 | -0 | -0 | -0 |
| EBIT | -2.858 | -7.488 | -36.962 | -106.843 | -70.094 | -46.310 | -49.461 |
| Net financials | -201 | -791 | 1.413 | 2.949 | 75 | 1.549 | 161 |
| Profit before tax | -3.059 | -8.280 | -35.549 | -103.894 | -70.019 | -44.762 | -49.300 |
| Tax | -0 | -1.486 | -5.796 | -5.500 | -5.500 | -5.500 | -5.500 |
| Net profit | -3.059 | -6.793 | -29.753 | -98.394 | -64.519 | -39.262 | -43.800 |
| Item | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|
| Total assets | 5.624 | 7.048 | 116.214 | 68.865 | 73.927 | 62.886 | 17.963 |
| Equity | -3.014 | -9.808 | 106.806 | 51.217 | 66.697 | 57.274 | 13.474 |
| Long-term debt | 8.396 | 0 | 0 | 0 | 0 | 0 | 0 |
| Short-term debt | 242 | 16.855 | 9.408 | 17.648 | 7.230 | 5.612 | 4.489 |
| Total debt | 8.638 | 16.855 | 9.408 | 17.648 | 7.230 | 5.612 | 4.489 |
EBITDA margin
-4946117300.0%
This company
15.8%
Market median
-31304539973% vs market
20192025
Equity ratio
75.0%
This company
38.2%
Market median
+96% vs market
20192025
Return on equity
-325.1%
This company
18.4%
Market median
-1867% vs market
20192025
Net profit margin
-4380000700.0%
This company
8.1%
Market median
-54074082816% vs market
20192025
Asset turnover
-2.35×
This company
1.12×
Market median
-310% vs market
20192025
Debt / equity
0.33×
This company
0.62×
Market median
+47% vs market
20192025
- Annual report 2025Filed via CVR / Virk · Period 2025-01-01 – 2025-12-31
- Annual report 2024Filed via CVR / Virk · Period 2024-01-01 – 2024-12-31
- Annual report 2023Filed via CVR / Virk · Period 2023-01-01 – 2023-12-31
- Annual report 2022Filed via CVR / Virk · Period 2022-01-01 – 2022-12-31
- Annual report 2021Filed via CVR / Virk · Period 2021-01-01 – 2021-12-31
- Annual report 2020Filed via CVR / Virk · Period 2020-01-01 – 2020-12-31
- Annual report 2019Filed via CVR / Virk · Period 2019-06-12 – 2019-12-31
| Name | Role | Member since | Age | Other directorships |
|---|---|---|---|---|
AH Unofficial title | Unofficial title | 2026 | — | — |
| Name | Role | Member since | Age | Other directorships |
|---|---|---|---|---|
| Board of Directors | 2021 | — | — | |
| Board of Directors | 2019 | — | — | |
| Board of Directors | 2021 | — | — | |
| Board of Directors | 2021 | — | — | |
| Board of Directors | 2023 | — | — | |
| Chairman | 2021 | — | — | |
| Chairman | 2019 | — | — | |
| Board of Directors | 2024 | — | — |
| Shareholder | Type | Ownership | Votes | Since |
|---|---|---|---|---|
LUNDBECKFOND INVEST A/S | Company | 25.0% | 25.0% | 2021 |
| Individual | 20.0% | 20.0% | 2024 | |
| Individual | 15.0% | 15.0% | 2024 | |
15-Bio ApS | Company | 10.0% | 10.0% | 2022 |
| Individual | 5.0% | 5.0% | 2021 | |
| Individual | 5.0% | 5.0% | 2024 | |
| Individual | 5.0% | 5.0% | 2021 | |
| Individual | 5.0% | 5.0% | 2021 |
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
LUNDBECKFONDEN
Cytoki Pharma ApS Board members of Cytoki Pharma ApS also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Anders Hagstrøm | Unofficial title | 0 companies |
| Daniel Bach Gonzalez | Board of Directors | 0 companies |
| Susanne Jørgensen | Board of Directors | 0 companies |
| Amanda Viven Gett-Chaperot | Board of Directors | 0 companies |
| Karen Ina Barbara Wagner | Board of Directors | 0 companies |
| Annegret Elisabeth De Baey-Diepolder | Board of Directors | 0 companies |
| Christian Ellebæk Elling | Chairman | 0 companies |
| Rasmus Jørgensen | Chairman | 0 companies |
| Klaus Andreas Dugi | Board of Directors | 0 companies |